Enoximone (MDL 17,043) for stable, chronic heart failure secondary to ischemic or idiopathic cardiomyopathy
- 1 September 1986
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 58 (7) , 589-595
- https://doi.org/10.1016/0002-9149(86)90281-x
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Alterations in left ventricular function, coronary hemodynamics and myocardial catecholamine balance with MDL 17043, a new inotropic vasodilator agent, in patients with severe heart failureJournal of the American College of Cardiology, 1985
- Comparative hemodynamic effects of intravenous dobutamine and MDL-17,043, a new cardioactive drug, in severe congestive heart failureAmerican Heart Journal, 1985
- Myocardial metabolic and hemodynamic effects of intravenous MDL-17,043, a new cardiotonic drug, in patients with chronic severe heart failureAmerican Heart Journal, 1984
- Intravenous and oral MDL 17043 (A new inotrope-vasodilator agent) in congestive heart failure: Hemodynamic and clinical evaluation in 38 patientsJournal of the American College of Cardiology, 1984
- Myocardial energetics and clinical response to the cardiotonic agent MDL 17043 in advanced heart failureJournal of the American College of Cardiology, 1984
- Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failureJournal of the American College of Cardiology, 1984
- Evaluation of a New Bipyridine Inotropic Agent — Milrinone — in Patients with Severe Congestive Heart FailureNew England Journal of Medicine, 1983
- The acute hemodynamic effects of a new agent, MDL 17,043, in the treatment of congestive heart failure.Circulation, 1983
- Biochemical Studies on the Mechanism of Cardiotonic Activity of MDL 17,043Journal of Cardiovascular Pharmacology, 1982
- Cardiovascular Properties of a New Cardiotonic AgentJournal of Cardiovascular Pharmacology, 1982